文献速递细菌感染、耐药与抗菌药物

金黄色葡萄球菌菌血症中IL-1β与IL-10宿主反应受抗菌治疗影响

Interleukin (IL)-1β and IL-10 Host Responses in Patients With Staphylococcus aureus Bacteremia Determined by Antimicrobial Therapy.
PubMed 文献 · Clin Infect Dis · 2020-01-01

多中心纳入59例金黄色葡萄球菌菌血症患者,比较β-内酰胺类与糖肽/脂肽类治疗对IL-1β和IL-10的影响。β-内酰胺类治疗者第3、7天IL-1β更高,IL-10下降更显著;基线IL-10升高与死亡和持续性菌血症相关。

要点

  • β-内酰胺类治疗者第3、7天IL-1β水平高于糖肽/脂肽类。
  • 基线IL-10升高与死亡和持续性菌血症相关。
  • β-内酰胺类治疗者IL-10下降更显著。

核心结论

  • β-内酰胺类对金黄色葡萄球菌菌血症重要,可能通过有利的宿主细胞因子反应发挥作用。

研究设计与样本

  • 三中心纳入2015-2017年59例金黄色葡萄球菌菌血症患者(47例MRSA,12例MSSA)。
  • 前48小时接受β-内酰胺类(n=24)或糖肽/脂肽类(n=35)治疗,检测第1、3、7天血清IL-1β和IL-10。

主要发现

  • 基线IL-10在死亡患者中升高(P = .008),在持续性菌血症患者中升高(P = .034),IL-1β无差异。
  • β-内酰胺类治疗者第3天IL-1β中位数高5.6 pg/mL(P = .007),第7天高10.9 pg/mL(P = .016)。
  • 体外加入IL-1受体拮抗剂anakinra降低全血杀灭葡萄球菌能力。
  • β-内酰胺类治疗者7天内IL-10下降比万古霉素或达托霉素更显著。

临床怎么用

  • 对金黄色葡萄球菌菌血症,β-内酰胺类可能通过调节宿主细胞因子反应带来获益。
  • MRSA患者中β-内酰胺类的辅助作用可能有助于 eliciting 有利的宿主细胞因子反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patient interleukin (IL)-1β and IL-10 responses early in Staphylococcus aureus bacteremia (SaB) are associated with bacteremia duration and mortality. We hypothesized that these responses vary depending on antimicrobial therapy, with particular interest in whether the superiority of β-lactams links to key cytokine pathways. METHODS: Three medical centers included 59 patients with SaB (47 methicillin-resistant S. aureus [MRSA], 12 methicillin-sensitive S. aureus [MSSA]) from 2015-2017. In the first 48 hours, patients were treated with either a β-lactam (n = 24), including oxacillin, cefazolin, or ceftaroline, or a glyco-/lipopeptide (n = 35), that is, vancomycin or daptomycin. Patient sera from days 1, 3, and 7 were assayed for IL-1β and IL-10 by enzyme-linked immunosorbent assay and compared using the Mann-Whitney U test. RESULTS: On presentation, IL-10 was elevated in mortality (P = .008) and persistent bacteremia (P = .034), while no difference occurred in IL-1β. Regarding treatment groups, IL-1β and IL-10 were similar prior to receiving antibiotic. Patients treated with β-lactam had higher IL-1β on days 3 (median +5.6 pg/mL; P = .007) and 7 (+10.9 pg/mL; P = .016). Ex vivo, addition of the IL-1 receptor antagonist anakinra to whole blood reduced staphylococcal killing, supporting an IL-1β functional significance in SaB clearance. β-lactam-treated patients had sharper declines in IL-10 than vancomycin or daptomycin -treated patients over 7 days. CONCLUSIONS: These data underscore the importance of β-lactams for SaB, including consideration that the adjunctive role of β-lactams for MRSA in select patients helps elicit favorable host cytokine responses.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Volk CF, Burgdorf S, Edwardson G, et al. Interleukin (IL)-1β and IL-10 Host Responses in Patients With Staphylococcus aureus Bacteremia Determined by Antimicrobial Therapy. Clin Infect Dis. 2020. PMID: 31365924. doi:10.1093/cid/ciz686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。